Regeneron Pharmaceuticals, Inc.

Kevin J Pobursky

Sean Stevens

Joel H Martin

Jeanette L Fairhurst

Nicholas J Papadopoulos

Tammy T Huang

Ashique Rafique

Margaret Karow

Eric L Smith

Gang Chen

James P Fandl

Eric B Smith

Joan A Windsor

Warren R Mikulka

Allen Radin

Ergang Shi

Raymond W Leidich

Diana M Ahrens

Marcela Torres

Tammy H Huang

Warren R Mikluka

Eric Smith

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a Kof about 500 pM or less and blocks IL-6 activity with an ICof 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

High affinity antibodies to human IL-6 receptor

Nucleic acids encoding high affinity antibodies to human IL-6 receptor

The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R&#x3b1;) with an affinity constant (K) of less than 200 pM, as measured by surface plasmon resonance, is provided.

High affinity human antibodies to human IL-4 receptor

An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18R&#x3b1;), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof.

High affinity human antibodies to human IL-18 receptor

The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.

Method of treating rheumatoid arthritis with an IL-6R antibody

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a Kof about 500 pM or less and blocks IL-6 activity with an ICof 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

Human antibodies to human IL-6 receptor

Growing community of inventors

Beacon, NY, United States of America

Kevin J Pobursky